Literature DB >> 29509393

Thiol-Reactive Bifunctional Chelators for the Creation of Site-Selectively Modified Radioimmunoconjugates with Improved Stability.

Pierre Adumeau1,2, Maria Davydova1, Brian M Zeglis1,2,3,4.   

Abstract

Maleimide-bearing bifunctional chelators have been used extensively for the site-selective bioconjugation and radiolabeling of peptides and proteins. However, bioconjugates obtained using these constructs inevitably suffer from limited stability in vivo, a trait that translates into suboptimal activity concentrations in target tissues and higher uptake levels in healthy, nontarget tissues. To circumvent this issue, phenyloxadiazolyl methylsulfones have previously been reported as alternatives to maleimides for thiol-based ligations, but these constructs have scarcely been used in the field of radiochemistry. In this report, we describe the synthesis of two thiol-reactive bifunctional chelators for 89Zr and 177Lu based on a new, easy-to-make phenyloxadiazolyl methylsulfone reagent, PODS. Radioimmunoconjugates created using these novel bifunctional chelators displayed in vitro stability that was higher than that of their maleimide-derived cousins. More importantly, positron emission tomography imaging in murine models of cancer revealed that a 89Zr-labeled radioimmunoconjugate created using a PODS-bearing bifunctional chelator produced a rate of uptake in nontarget tissues that is significantly lower than that of its analogous maleimide-based counterpart.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29509393      PMCID: PMC6523022          DOI: 10.1021/acs.bioconjchem.8b00081

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  10 in total

Review 1.  New Approaches to SCLC Therapy: From the Laboratory to the Clinic.

Authors:  John T Poirier; Julie George; Taofeek K Owonikoko; Anton Berns; Elisabeth Brambilla; Lauren A Byers; David Carbone; Huanhuan J Chen; Camilla L Christensen; Caroline Dive; Anna F Farago; Ramaswamy Govindan; Christine Hann; Matthew D Hellmann; Leora Horn; Jane E Johnson; Young S Ju; Sumin Kang; Mark Krasnow; James Lee; Se-Hoon Lee; Jonathan Lehman; Benjamin Lok; Christine Lovly; David MacPherson; David McFadden; John Minna; Matthew Oser; Keunchil Park; Kwon-Sik Park; Yves Pommier; Vito Quaranta; Neal Ready; Julien Sage; Giorgio Scagliotti; Martin L Sos; Kate D Sutherland; William D Travis; Christopher R Vakoc; Sarah J Wait; Ignacio Wistuba; Kwok Kin Wong; Hua Zhang; Jillian Daigneault; Jacinta Wiens; Charles M Rudin; Trudy G Oliver
Journal:  J Thorac Oncol       Date:  2020-02-01       Impact factor: 15.609

2.  Synthesis and Bioconjugation of Thiol-Reactive Reagents for the Creation of Site-Selectively Modified Immunoconjugates.

Authors:  Maria Davydova; Guillaume Dewaele Le Roi; Pierre Adumeau; Brian M Zeglis
Journal:  J Vis Exp       Date:  2019-03-06       Impact factor: 1.355

3.  5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Authors:  Dylan J Kahl; Kim M Hutchings; Erika Mathes Lisabeth; Andrew J Haak; Jeffrey R Leipprandt; Thomas Dexheimer; Dinesh Khanna; Pei-Suen Tsou; Phillip L Campbell; David A Fox; Bo Wen; Duxin Sun; Marc Bailie; Richard R Neubig; Scott D Larsen
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

4.  DiPODS: A Reagent for Site-Specific Bioconjugation via the Irreversible Rebridging of Disulfide Linkages.

Authors:  Elaheh Khozeimeh Sarbisheh; Guillaume Dewaele-Le Roi; Whitney E Shannon; Sally Tan; Yujia Xu; Brian M Zeglis; Eric W Price
Journal:  Bioconjug Chem       Date:  2020-11-19       Impact factor: 4.774

Review 5.  Perspectives on metals-based radioimmunotherapy (RIT): moving forward.

Authors:  Jordan M White; Freddy E Escorcia; Nerissa T Viola
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

Review 6.  Current Perspectives on 89Zr-PET Imaging.

Authors:  Joon-Kee Yoon; Bok-Nam Park; Eun-Kyoung Ryu; Young-Sil An; Su-Jin Lee
Journal:  Int J Mol Sci       Date:  2020-06-17       Impact factor: 5.923

Review 7.  The Chemistry Behind ADCs.

Authors:  Vesela Kostova; Patrice Désos; Jérôme-Benoît Starck; Andras Kotschy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07

8.  Synthesis and Comparative In Vivo Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET.

Authors:  Sai Kiran Sharma; Pierre Adumeau; Outi Keinänen; Vikram Sisodiya; Hetal Sarvaiya; Robert Tchelepi; Joshua A Korsen; Jacob Pourat; Kimberly J Edwards; Ashwin Ragupathi; Omar Hamdy; Laura R Saunders; Charles M Rudin; John T Poirier; Jason S Lewis; Brian M Zeglis
Journal:  Bioconjug Chem       Date:  2021-04-09       Impact factor: 4.774

9.  A Systematic Evaluation of Antibody Modification and 89Zr-Radiolabeling for Optimized Immuno-PET.

Authors:  Sai Kiran Sharma; Jonathan M Glaser; Kimberly J Edwards; Elaheh Khozeimeh Sarbisheh; Akam K Salih; Jason S Lewis; Eric W Price
Journal:  Bioconjug Chem       Date:  2020-04-01       Impact factor: 6.069

10.  Thiol-Reactive PODS-Bearing Bifunctional Chelators for the Development of EGFR-Targeting [18F]AlF-Affibody Conjugates.

Authors:  Chiara Da Pieve; Ata Makarem; Stephen Turnock; Justyna Maczynska; Graham Smith; Gabriela Kramer-Marek
Journal:  Molecules       Date:  2020-03-29       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.